Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line

Gynecological Endocrinology

Volumn 23, Issue 4, 2007, Pages 193-197

  Paris, Françoise ^a,b   Rabeolina, Fangia ^b   Balaguer, Patrick ^b   Bacquet, Aleth ^c   Sultan, Charles ^a,b  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c Laboratoire EFFIK   (France)

Author keywords

Androgen receptor; Antiandrogen; Female acne

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYPROTERONE ACETATE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; METRIBOLONE; NORELGESTROMIN; NORGESTIMATE; TRITIUM;

ACNE; ANIMAL CELL; ANTIANDROGENIC ACTIVITY; ARTICLE; CELL LINE; CELL STRAIN COS7; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HORMONE INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; TRANSACTIVATION; TRANSCRIPTION INITIATION;

ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; COS CELLS; CYPROTERONE ACETATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEVONORGESTREL; NORGESTREL; PROTEIN BINDING; RECEPTORS, ANDROGEN; TIME FACTORS; TRANSFECTION;

EID: 34248593017     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590701214414     Document Type: Article

References (26)

1. Lucky AW. Hormonal correlates of acne and hirsutism. Am J Med 1995;98(Suppl 1A):89S-94S.
2. Burkman RT Jr. The role of oral contraceptives in the treatment of hyperandrogenic disorders. Am J Med 1995;98(Suppl 1A):S130-S136.
3. Lucky AW, Henderson TA, Olson WH, Robisch DM, Lebwohl M, Swinyer LJ. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol 1997;37:746-754.
4. Redmond GP, Olson WH, Lippman JS, Kafrissen ME, Jones TM, Jorizzo JL. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol 1997;89:615-622.
5. Olson WH, Lippman JS, Robisch DM. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris. Int J Fertil 1998;6:286-290.
6. Janaud A, Rouffy J, Upmalis D, Dain MP. A comparison study of lipid and androgen metabolism with triphasic oral contraceptive formulations containing norgestimate or levonorgestrel. Acta Obstet Gynecol Scand Suppl 1992;156:33-38.
7. Burkman R Jr, Kafrissen M, Olson W, Osterman J. Lipid and carbohydrate effects of a new triphasic oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1992;156:5-8.
8. Gobinet J, Poujol N, Sultan C. Molecular action of androgens. Mol Cell Endocrinol 2002;198:15-24.
9. Phillips A, Hahn DW, Klimek S, McGuire JL. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 1993;36:181-192.
10. Phillips A. The selectivity of a new progestin. Acta Obstet Gynecol Scand Suppl 1990;152:21-24.
11. Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG, Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 2003;67:93-99.
12. Terouanne B, Tahiri B, Georget V, Belon C, Poujol N, Avances C, Orio F Jr, Balaguer P, Sultan C. A stable prostatic bioluminescent cell line to investigate androgen and antiandrogen effects. Mol Cell Endocrinol 2000;160:39-49.
13. Terouanne B, Paris F, Servant N, Georget V, Sultan C. Evidence that chlormadinone acetate exhibits antiandrogenic activity in androgen-dependent cell line. Mol Cell Endocinol 2002;198:143-147.
14. Nirde P, Terouanne B, Gallais N, Sultan C, Auzou G. Antimineralocorticoid 11β-substituted spirolactones exhibit androgen receptor agonistic activity: a structure function study. Mol Pharmacol 2001;59:1307-1313.
15. Georget V, Lobaccaro JM, Terouanne B, Mangeat P, Nicolas JC, Sultan C. Trafficking of the androgen receptor in living cells with fused green fluorescent protein-androgen receptor. Mol Cell Endocrinol 1997;129:17-26.
16. Avances C, Georget V, Terouanne B, Orio F, Cussenot O, Mottet N, Costa P, Sultan C. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.Mol Cell Endocrinol 2001;184:13-24.
17. Chapdelaine A, Desmarais J, Derman RJ. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989;34:347-352.
18. Juchem M, Pollow K, Elger W, Hoffmann G, Mobus V. Receptor binding of norgestimate - a new orally active synthetic progestational compound. Contraception 1993;47:283-294.
19. London RS, Chapdelaine A, Upmalis D, Olson W, Smith J. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand Suppl 1992;156:9-14.
20. Andolsek K. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent. Acta Obstet Gynecol Scand Suppl 1992;156:22-26.
21. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5α-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000;14:223-230.
22. Labrie C, Cusan L, Plante M, Lapointe S, Labrie F. Analysis of the androgenic activity of synthetic 'rogestins'currently used for the treatment of prostate cancer. J Steroid Biochem 1987;28:379-384.
23. Plante M, Lapointe S, Labrie F. Stimulatory effect of synthetic progestins currently used for the treatment of prostate cancer on growth of the androgen-sensitive Shionogi tumor in mice. J Steroid Biochem 1988;31:61-64.
24. Luthy IA, Begin DJ, Labrie F. Androgenic activity of synthetic progestins and spironolactone in androgen-sensitive mouse mammary carcinoma (Shionogi) cells in culture. J Steroid Biochem 1988;31:845-852.
25. Poulin R, Baker D, Poirier D, Labrie F. Multiple actions of synthetic 'progestins' on the growth of ZR-75-1 human breast cancer cells: an in vitro model for the simultaneous assay of androgen, progestin, estrogen, and glucocorticoid agonistic and antagonistic activities of steroids. Breast Cancer Res Treat 1991;17:197-210.
26. Sator PG, Schmidt JB, Hönigsmann H. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. Dermatology 2003;206:241-248.